(Total Views: 629)
Posted On: 02/16/2025 2:37:14 AM
Post# of 150397
Re: Carsmax177 #150208
Nice catch. Incidentally, GSK is paying a billion dollars plus possible milestone of $150K for a company's whose IDRX-42 is an ongoing phase I/Ib trial in patients with advanced GIST, gastrointestinal stromal tumors.
I mention this because I know of another company whose drug has done well in several Phase II and III trials for a wide variety of broad and lucrative indications. Wonder how much that company is worth?
I mention this because I know of another company whose drug has done well in several Phase II and III trials for a wide variety of broad and lucrative indications. Wonder how much that company is worth?
(9)
(0)Scroll down for more posts ▼
